Market Overview

Benzinga's Top #PreMarket Gainers

Related ALNY
Alnylam Expands Hepatic Infectious Disease Pipeline; Adds ALN-HDV For The Treatment Of Chronic Hepatitis Delta Virus Infection And ALN-PDL For The Treatment Of Chronic Liver Infections
Alnylam Completes Phase 2 Enrollment
Action in Ebola-Related Stocks (Fox Business)
Related MRK
Merck Announces That IMPROVE-IT Achieved Primary Endpoint; Data To Be Presented At American Heart Association Scientific Sessions Today
Merck Announces Results From Phase 2 Study Of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir In Genotype 1 Infected Treatment-Naïve And Difficult-To-Cure Patients
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

Alnylam Pharmaceuticals (NASDAQ: ALNY) shares jumped 35.93% to $90.00 in pre-market trading after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

Beam (NYSE: BEAM) shares gained 25.93% to $84.35 in the pre-market after the company agreed to be acquired by Suntory Holdings for $83.50 per share in cash.

NII Holdings (NASDAQ: NIHD) surged 20.81% to $2.70 in the pre-market session after the company and Telefonica signed agreements to provide wholesale voice and data services to Nextel in Brazil and Mexico.

Clovis Oncology (NASDAQ: CLVS) soared 6.99% to $79.15 in the pre-market trading after the company announced 2014 objectives and financial outlook.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers

 

Related Articles (ALNY + BEAM)

Around the Web, We're Loving...

Get Benzinga's Newsletters